Molina Healthcare IncNYSE: MOH
Health Care · Managed Health Care
$195.55
+0.01%
Vol: 345K
Research Digest
Friday, June 19, 2026
Molina Healthcare wins Illinois Medicaid contract and receives analyst price target raise; stock up 37% over 90 days.
Molina Healthcare won a significant Illinois Medicaid managed care contract in early June 2026, a key catalyst that has helped push shares up approximately 36.7% over the past 90 days and 8.3% over the past 30 days, with the stock trading around $195-$200. Mizuho raised its price target to $215 from $200 on June 8, 2026, reflecting confidence in the contract win and Q1 2026 margin improvements. Wells Fargo maintained a Hold rating on June 4. The company announced Q2 2026 earnings will be released July 22, 2026. Molina serves low-income individuals through Medicaid, Medicare, and Marketplace programs across 21 states, and the Illinois award reinforces its geographic expansion strategy. The forward P/E of approximately 9.1x remains below industry peers, suggesting the stock may still have room to run despite the strong recent rally.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Molina Healthcare stock saw notable insider selling on May 15 following its May 8 Investor Day where management outlined 2029 financial targets but warned of substantial regulatory and Medicaid cost risks.Mixed▶
Molina Healthcare hosted its Investor Day Conference on May 8, 2026, where management outlined long-term financial targets and detailed strategic and operational plans across Medicaid, Medicare, and Marketplace businesses. While management presented growth, AI and program initiatives, they warned the 2029 outlook faces substantial regulatory and cost risks. On May 11, shareholders approved governance and bylaw changes, and Truist raised its price target to $205 from $180. However, Barclays maintained a Sell rating on May 12, and a top executive made a notable insider stock sale on May 15. As of May 20, the stock traded in the $180-$188 range with concerns persisting about future Medicaid spending uncertainty. Overall sentiment remains cautious amid regulatory headwinds.
May 20Molina Healthcare outlines long-term 2029 financial targets at May 8 Investor Day and receives mixed analyst reactions.Mixed▶
Molina Healthcare held its Investor Day on May 8, 2026, outlining ambitious long-term targets including premiums near $48B by 2027 and revenue of $49.2B by 2029, with embedded earnings exceeding $11/share targeted for 2027-2029. CEO Joseph Zubretsky called 2026 a trough year for Medicaid industry margins. The stock rose 3.45% on May 12 to $191.58, but Zacks Research cut Q2 2026 EPS estimate to $1.27 from $1.68. Truist raised the price target to $205 from $180 on May 11, while Barclays maintained a Sell rating. Shareholders approved governance and bylaw changes on May 11, and a top executive made a notable insider sale on May 15.
May 19Molina Healthcare targets $49.2B revenue by 2029 at May 8 Investor Day; Truist raises PT to $205 as stock gains 3.45% to $191.58.Positive▶
Molina Healthcare hosted its 2026 Investor Day on May 8, outlining long-term financial targets including premiums near $48 billion by 2027 and revenue of $49.2 billion by 2029, supported by growth, AI, and program initiatives. Management cautioned the 2029 outlook faces substantial regulatory and cost risks as 2026 remains a 'trough year' for Medicaid industry margins. Truist raised its price target to $205 from $180 on May 11, and Baird raised to $163 from $124 the same day, while Barclays maintained a Sell rating. The stock rose 3.45% on May 12 to $191.58, having rallied 26.64% over the prior month as investors look past the trough year. Shareholders approved governance and bylaw changes at the May 11 meeting, and several top executives executed notable insider stock sales in mid-May.
May 18Molina Healthcare shares slipped 3.06% in the last 24 hours as executive insider sales on May 12-13 contrast with Truist May 11 price target hike to $205.Mixed▶
Molina Healthcare stock declined 3.06% in the past 24 hours to $185.94, weighed down by two executive insider stock sales reported on May 12 and May 13, 2026. Truist raised its price target to $205 from $180 on May 11, 2026 following Molina May 8 Investor Day, where the company laid out long-term targets including premiums near $48B by 2027 and revenue of $49.2B by 2029. Shareholders also approved governance and bylaw changes including a 20% threshold for stockholders to call special meetings at the May 6 annual meeting. CEO Joseph Zubretsky has framed 2026 as a trough year for Medicaid industry margins with embedded earnings exceeding $11.00/share targeted for 2027-2029. Mixed signals as analyst optimism collides with insider selling.
May 15Molina Healthcare hosts May 8 Investor Day outlining AI deployment and capital allocation; CLO sells 17,811 shares May 11.Positive▶
Molina Healthcare hosted its Investor Day Conference on May 8, 2026, outlining long-term financial updates with initiatives including AI deployment, capital allocation priorities, and program implementations. At the May 6, 2026 annual meeting, shareholders approved an amendment allowing stockholders holding at least 20% of voting power to call special meetings, with ten directors elected. Chief Legal Officer Jeff D. Barlow reported an open-market sale of 17,811 shares on May 11, 2026 at a VWAP of $186.12. Shares last closed at $191.97, up 28.0% over the past 30 days and 7.6% YTD, but down 38.4% over the past year. The most recent analyst rating is Buy with a $250 price target.
May 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 13Molina Healthcare unveiled long-term targets at May 8 Investor Day, targeting $25 adjusted EPS by 2029 vs $5 in 2026, while Baird raised PT to $163 on May 11.Mixed▶
Molina hosted its 2026 Investor Day on May 8, outlining a long-term strategic plan targeting adjusted EPS of $25 by 2029, up from at least $5 in 2026, driven by pretax margin expansion from less than 1% to about 2.5%. The stock fell 3.1% to $185.94 on May 8 as investors weighed the ambitious 2029 outlook against substantial regulatory and cost risks flagged by management. On May 6, shareholders approved governance amendments allowing 20% holders to call special meetings and elected ten directors. Truist raised its price target to $205 from $180 and Baird raised its target to $163 from $124 on May 11. The risk is execution of pretax margin expansion against Medicaid cost trend headwinds and rate-setting uncertainty.
May 12Molina Healthcare unveiled a 2029 adjusted EPS target of $25 at its May 8 Investor Day, prompting Truist to raise its target to $205 and Baird to $163.Mixed▶
At its May 8, 2026 Investor Day, Molina Healthcare laid out long-term targets including adjusted EPS of $25 by 2029 while reaffirming FY26 adjusted EPS of at least $5. Truist raised its price target to $205 from $180 (Hold) and Baird lifted its target to $163 on May 11. Shareholders at the May 6 annual meeting approved a special-meeting threshold of 20% ownership, elected ten directors, and ratified EY as auditor. Bear case: shares fell 3.1% on Investor Day to ~$185.94 as the market questioned the credibility of out-year targets given near-term Medicaid redetermination headwinds, marketplace risk-adjustment volatility, and execution risk on the multi-year EPS bridge.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| UNHUNITEDHEALTH | $400.38 | +0.21% | +4.6% | 19.2x | 0.65 | $364.1B |
| ELVELEVANCE | $388.43 | -0.73% | -1.9% | 13.3x | 0.68 | $84.4B |
| HUMHUMANA | $360.23 | -0.49% | +18.6% | 22.9x | 0.77 | $43.3B |
| CNCCENTENE | $60.99 | +0.58% | +4.7% | 13.7x | 1.09 | $30.1B |
| MOHMOLINA | $195.55 | +0.01% | +7.2% | 21.1x | 0.80 | $10.2B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.